SUPPORTING INFECTIOUS DISEASE RESEARCH

Peptide Array, Hepatitis C Virus, J4, NS5A Protein

Catalog No. NR-3745

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor:

BEI Resources

Manufacturer:

Bio-Synthesis, Inc.

Product Description:

The 71-peptide array spans the NS5A protein of hepatitis C virus, J4 (genotype 1b; GenPept: AAC15722).¹ Peptides are 13- to 19-mers, with 11 amino acid overlaps. Please see Table 1 for length and sequence of individual peptides.

Material Provided:

Peptides are provided lyophilized at 1 mg per vial.

Packaging/Storage:

Lyophilized peptides should be placed in a closed dry environment with dessicants and stored at -20°C or colder immediately upon arrival. A frost-free freezer should be avoided, since changes in moisture and temperature may affect peptide stability.

Solubility:

Solubility may vary based on the amino acid content of the individual peptide (see Table 2).

Reconstitution:

Lyophilized peptides should be warmed to room temperature for 1 hour prior to reconstitution. They should be dissolved at the highest possible concentration, and then diluted with water or buffer to the working concentration. Buffer should be added only after the peptide is completely in solution because salts may cause aggregation.

The most common dissolution process is 1 mg of peptide in 1 mL of sterile, distilled water. Peptides that are not soluble in water can almost always be dissolved in DMSO. Once a peptide is in solution, the DMSO can be slowly diluted with aqueous medium. Care must be taken to ensure that the peptide does not begin to precipitate out of solution. For cellbased assays, 0.5% DMSO in medium is usually welltolerated.

Sonication and/or the addition of small amounts of dilute (10%) aqueous acetic acid for basic peptides, aqueous ammonia for acidic peptides or acetonitrile may also help dissolution (see Table 2). These solvents may not be

appropriate for certain applications, including cell-based assays.

Storage of Reconstituted Peptides:

The shelf life of peptides in solution is very limited, especially for sequences containing cysteine, methionine, tryptophan, asparagine, glutamine, and N-terminal glutamic acid. In general, peptides may be aliquoted and stored in solution for a few days at -20°C or colder. For long-term storage, peptides should be re-lyophilized and stored at -20°C or colder. If long-term storage in solution is unavoidable, peptide solutions should be buffered to pH 5-6, aliquoted and stored at -20°C or colder. Freeze-thaw cycles should be avoided.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Peptide Array, Hepatitis C Virus, J4, NS5A Protein, NR-3745."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. <u>Biosafety in</u> <u>Microbiological and Biomedical Laboratories</u>. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at <u>www.beiresources.org</u>.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC[®] nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC[®] nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC[®] and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC[®], their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898 **b**|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

Use Restrictions:

This material is distributed for internal research, noncommercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale. This material may be subject to third party patent rights.

References:

 Yanagi, M., et al. "Transcripts of a Chimeric cDNA Clone of Hepatitis C Virus Genotype 1b Are Infectious *in Vivo.*" <u>Virology</u> 244 (1998): 161-172. PubMed: 9581788. GenPept: AAC15722.

 $\mathsf{ATCC}^{\circledast}$ is a trademark of the American Type Culture Collection.



	Table 1				
Peptide	Length	Sequence			
1 of 71	16	1 SGSWLRDVWDWICTVL 16			
2 of 71	18	6 RDVWDWICTVLTDFKTWL 23			
3 of 71	18	13 CTVLTDFKTWLQSKLLPR 30			
4 of 71	18	20 KTWLQSKLLPRLPGVPFL 37			
5 of 71	18	27 LLPRLPGVPFLSCQRGYK 44			
6 of 71	15	34 VPFLSCQRGYKGVWR 48			
7 of 71	16	38 SCQRGYKGVWRGDGIM 53			
8 of 71	19	43 YKGVWRGDGIMQTTCPCGA 61			
9 of 71	18	51 GIMQTTCPCGAQIAGHVK 68			
10 of 71	18	58 PCGAQIAGHVKNGSMRIV 75			
11 of 71	18	65 GHVKNGSMRIVGPRTCSN 82			
12 of 71	17	72 MRIVGPRTCSNTWHGTF 88			
13 of 71	16	78 RTCSNTWHGTFPINAY 93			
14 of 71	18	83 TWHGTFPINAYTTGPCTP 100			
15 of 71	17	90 INAYTTGPCTPSPAPNY 106			
16 of 71	18	96 GPCTPSPAPNYSRALWRV 113			
17 of 71	17	103 APNYSRALWRVAAEEYV 119			
18 of 71	16	109 ALWRVAAEEYVEVTRV 124			
19 of 71	17	114 AAEEYVEVTRVGDFHYV 130			
20 of 71	19	120 EVTRVGDFHYVTGMTTDNV 138			
21 of 71	17	128 HYVTGMTTDNVKCPCQV 144			
22 of 71	17	134 TTDNVKCPCQVPAPEFF 150			
23 of 71	18	140 CPCQVPAPEFFTEVDGVR 157			
24 of 71	18	147 PEFFTEVDGVRLHRYAPA 164			
25 of 71	17	154 DGVRLHRYAPACKPLLR 170			
26 of 71	18	160 RYAPACKPLLREDVTFQV 177			
27 of 71	18	167 PLLREDVTFQVGLNQYLV 184			
28 of 71	15	174 TFQVGLNQYLVGSQL 188			

bei resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

	Table 1				
Peptide	Length	Sequence			
29 of 71	19	178 GLNQYLVGSQLPCEPEPDV 196			
30 of 71	18	186 SQLPCEPEPDVTVLTSML 203			
31 of 71	17	193 EPDVTVLTSMLTDPSHI 209			
32 of 71	18	199 LTSMLTDPSHITAETAKR 216			
33 of 71	15	206 PSHITAETAKRRLAR 220			
34 of 71	18	210 TAETAKRRLARGSPPSLA 227			
35 of 71	18	217 RLARGSPPSLASSSASQL 234			
36 of 71	18	224 PSLASSSASQLSAPSLKA 241			
37 of 71	17	231 ASQLSAPSLKATCTTHH 247			
38 of 71	18	237 PSLKATCTTHHDSPDADL 254			
39 of 71	18	244 TTHHDSPDADLIEANLLW 261			
40 of 71	15	251 DADLIEANLLW RQEM 265			
41 of 71	18	255 IEANLLW RQEMGGNITRV 272			
42 of 71	18	262 RQEMGGNITRVESENKVV 279			
43 of 71	16	269 ITRVESENKVVILDSF 284			
44 of 71	16	274 SENKVVILDSFEPLHA 289			
45 of 71	18	279 VILDSFEPLHAEGDEREI 296			
46 of 71	18	286 PLHAEGDEREISVAAEIL 303			
47 of 71	17	293 EREISVAAEILRKSRKF 309			
48 of 71	18	299 AAEILRKSRKFPSALPIW 316			
49 of 71	16	306 SRKFPSALPIWARPDY 321			
50 of 71	16	311 SALPIWARPDYNPPLL 326			
51 of 71	15	316 WARPDYNPPLLESWK 330			
52 of 71	16	320 DYNPPLLESWKDPDYV 335			
53 of 71	16	325 LLESWKDPDYVPPVVH 340			
54 of 71	15	330 KDPDYVPPVVHGCPL 344			
55 of 71	16	334 YVPPVVHGCPLPPTKA 349			
56 of 71	18	339 VHGCPLPPTKAPPIPPPR 356			
57 of 71	18	346 PTKAPPIPPRRKRTVVL 363			
58 of 71	16	353 PPPRRKRTVVLTESNV 368			
59 of 71	18	358 KRTVVLTESNVSSALAEL 375			
60 of 71	16	365 ESNVSSALAELATKTF 380			
61 of 71	18	370 SALAELATKTFGSSGSSA 387			
62 of 71	17	377 TKTFGSSGSSAVDSGTA 393			
63 of 71	18	383 SGSSAVDSGTATALPDLA 400			
64 of 71	17	390 SGTATALPDLASDDGDK 406			
65 of 71	18	396 LPDLASDDGDKGSDVESY 413			
66 of 71	17	403 DGDKGSDVESYSSMPPL 419			
67 of 71	18	409 DVESYSSMPPLEGEPGDP 426			
68 of 71	18	416 MPPLEGEPGDPDLSDGSW 433			
69 of 71	18	423 PGDPDLSDGSWSTVSEEA 440			
70 of 71	16	430 DGSWSTVSEEASEDVV 445			
71 of 71	13	435 TVSEEASEDVVCC 447			

BEI Resources www.beiresources.org E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898 SUPPORTING INFECTIOUS DISEASE RESEARCH

	Table 2				
Peptide	Solubility	Solvent			
1 of 71	1 mg/mL	50% acetic acid in water			
2 of 71	1 mg/mL	50% acetic acid in water			
3 of 71	1 mg/mL	50% acetic acid in water			
4 of 71	1 mg/mL	50% acetic acid in water			
5 of 71	1 mg/mL	Water			
6 of 71	1 mg/mL	50% acetic acid in water			
7 of 71	1 mg/mL	50% acetic acid in water			
8 of 71	1 mg/mL	50% acetic acid in water			
9 of 71	1 mg/mL	Water			
10 of 71	1 mg/mL	50% acetic acid in water			
11 of 71	1 mg/mL	50% acetic acid in water			
12 of 71	1 mg/mL	50% acetic acid in water			
13 of 71	1 mg/mL	50% acetic acid in water			
14 of 71	1 mg/mL	50% acetic acid in water			
15 of 71	1 mg/mL	50% acetic acid in water			
16 of 71	1 mg/mL	50% acetic acid in water			
17 of 71	1 mg/mL	50% acetic acid in water			
18 of 71	1 mg/mL	50% acetic acid in water			
19 of 71	1 mg/mL	50% acetic acid in water			
20 of 71	1 mg/mL	50% acetic acid in water			
21 of 71	1 mg/mL	50% acetic acid in water			
22 of 71	1 mg/mL	50% acetic acid in water			
23 of 71	1 mg/mL	50% acetic acid in water			
24 of 71	1 mg/mL	50% acetic acid in water			
25 of 71	1 mg/mL	70% acetonitrile in water			
26 of 71	1 mg/mL	70% acetonitrile in water			
27 of 71	1 mg/mL	50% acetic acid in water			
28 of 71	1 mg/mL	50% acetic acid in water			
29 of 71	1 mg/mL	50% acetic acid in water			
30 of 71	1 mg/mL	50% acetic acid in water			
31 of 71	1 mg/mL	50% acetic acid in water			
32 of 71	1 mg/mL	50% acetic acid in water			
33 of 71	1 mg/mL	50% acetic acid in water			
34 of 71	1 mg/mL	50% acetic acid in water			
35 of 71	1 mg/mL	50% acetic acid in water			
36 of 71	1 mg/mL	50% acetic acid in water			
37 of 71	1 mg/mL	Water			
38 of 71	1 mg/mL	50% acetic acid in water			
39 of 71	1 mg/mL	50% acetic acid in water			

SUPPORTING INFECTIOUS DISEASE RESEARCH

	Table 2				
Peptide	Solubility	Solvent			
40 of 71	1 mg/mL	50% acetic acid in water			
41 of 71	1 mg/mL	50% acetic acid in water			
42 of 71	1 mg/mL	50% acetic acid in water			
43 of 71	1 mg/mL	50% acetic acid in water			
44 of 71	1 mg/mL	50% acetic acid in water			
45 of 71	1 mg/mL	50% acetic acid in water			
46 of 71	1 mg/mL	50% acetic acid in water			
47 of 71	1 mg/mL	50% acetic acid in water			
48 of 71	1 mg/mL	50% acetic acid in water			
49 of 71	1 mg/mL	50% acetic acid in water			
50 of 71	1 mg/mL	50% acetic acid in water			
51 of 71	1 mg/mL	50% acetic acid in water			
52 of 71	1 mg/mL	50% acetic acid in water			
53 of 71	1 mg/mL	50% acetic acid in water			
54 of 71	1 mg/mL	50% acetic acid in water			
55 of 71	1 mg/mL	50% acetic acid in water			
56 of 71	1 mg/mL	50% acetic acid in water			
57 of 71	1 mg/mL	50% acetic acid in water			
58 of 71	1 mg/mL	50% acetic acid in water			
59 of 71	1 mg/mL	50% acetic acid in water			
60 of 71	1 mg/mL	50% acetic acid in water			
61 of 71	1 mg/mL	50% acetic acid in water			
62 of 71	1 mg/mL	50% acetic acid in water			
63 of 71	1 mg/mL	50% acetic acid in water			
64 of 71	1 mg/mL	70% acetonitrile in water			
65 of 71	1 mg/mL	50% acetic acid in water			
66 of 71	1 mg/mL	50% acetic acid in water			
67 of 71	1 mg/mL	50% acetic acid in water			
68 of 71	1 mg/mL	50% acetic acid in water			
69 of 71	1 mg/mL	50% acetic acid in water			
70 of 71	1 mg/mL	100% DMSO			
71 of 71	1 mg/mL	100% DMSO			